Gsa Capital Partners LLP Apellis Pharmaceuticals, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 7,835 shares of APLS stock, worth $203,710. This represents 0.02% of its overall portfolio holdings.
Number of Shares
7,835
Previous 28,584
72.59%
Holding current value
$203,710
Previous $824,000
69.66%
% of portfolio
0.02%
Previous 0.06%
Shares
11 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$318 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$309 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$307 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$261 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$250 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.86B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...